Radioimmunotherapy for B-cell non-Hodgkin lymphomas

Cancer Control

Volumn 19, Issue 3, 2012, Pages 196-203

  Tomblyn, Michael ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD22 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; EPRATUZUMAB Y 90; FLUDARABINE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB; VELTUZUMAB; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FOLLICULAR LYMPHOMA; HEMATOLOGIC DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84864504946     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900304     Document Type: Article

References (60)

1. Dixon KL. The radiation biology of radioimmunotherapy. Nucl Med Commun. 2003;24(9):951-957.
2. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(10):2453-2463.
3. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001; 19(19):3918-3928.
4. Kylstra JW, Witzig TE, Huang M, et al. Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: meta-analysis of fi ve clinical trials and 9 years of post-approval safety data. J Clin Oncol. 2011;29(15 suppl):8048. Abstract.
5. Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Ylabeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43(2):267-272.
6. Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2004;4(1):18-26.
7. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259-1266.
8. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18(6):1316-1323.
9. Gockerman J, Gregory S, Harwood S, et al. Interim effi cacy results of Bexxar in a large multicenter expanded access study. Proc Am Soc Clin Oncol. 2001:20(pt 1):285a. Abstract 1137.
10. Horning SJ, Younes A, Jain V, et al. Effi cacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23(4):712-719.
11. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99(12):4336-4342.
12. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20(15):3262-3269.
13. Gordon LI, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004;5(2):98-101.
14. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47(4):629-636.
15. Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival. A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol. 2010;28(5):822-829.
16. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after fi rst remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156-5164.
17. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for pre viously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003;102:1606-1612.
18. Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus shortduration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as fi rst-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma. 2009;9(3):223-228.
19. Jacobs SA, Swerdlow SH, Kant J, et al. Phase II trial of shortcourse CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008;14(21):7088-7094.
20. McLaughlin P, Neelapu S, Fanale M, et al. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts). 2008;112(11):3056.
21. Karmali R, Kassar M, Jimenez A, et al. Update on a prospective study evaluating the safety and effi cacy of combination therapy with fl udarabine, mitoxantrone and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front line therapy for patients with indolent lymphomas. Blood (ASH Annual Meeting Abstracts). 2010;116(21):3946.
22. Zinzani PL, Tani M, Pulsoni A, et al. A phase II trial of short course fl udarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann Oncol. 2012;23(2):415-420.
23. Rose AC, Garrett G, Seward M, et al. A systematic review and meta-analysis of radioimmunotherapy consolidation for untreated patients with follicular lymphoma (FL). Blood (ASH Annual Meeting Abstracts). 2011;118(21):101.
24. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5):441-449.
25. Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced stage, follicular lymphoma: median 10 year follow-up results. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3759.
26. Pica G, Nati S, Vitolo U, et al. Safety and effi cacy of 90Y ibritumomab tiuxetan (Zevalin) for untreated follicular non-Hodgkin's lymphoma (FL) patients, an Italian cooperative study. Blood (ASH Annual Meeting Abstracts). 2011;118(21):100.
27. Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fl udarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer. 2008;112(4):856-862.
28. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: fi ve-year followup of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006; 24(25):4143-4149.
29. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fl udarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696-5704.
30. Fowler NH, Neelapu SS, Fanale MA, et al. Phase II study with R-FND followed by 90-Y ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance for untreated high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118(21):99.
31. Morschhauser F, Illidge T, Huglo D, et al. Effi cacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110(1):54-58.
32. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008;19(4):769-773.
33. Hamlin PA, Moskowitz CH, Wegner B, et al. Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL. Ann Oncol. 2008;19(suppl 4): iv100. Abstract 054.
34. Zinzani PL, Rossi G, Franceschetti S, et al. Phase II trial of shortcourse R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res. 2010;16(15):3998-4004.
35. Friedberg JW, Unger JM, Burack WR, et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group Protocol S0433. Blood (ASH Annual Meeting Abstracts). 2010;116(21):590.
36. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:5213-5218.
37. Zelenetz AD, Noy A, Pandit-Taskar N, et al. Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol. 2006;24(18 suppl):7560. Abstract.
38. Smith M, Chen L, Gordon LI, et al. Phase II study of R-CHOP and 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma (E1499). J Clin Oncol. 2006;24(18 suppl):7503. Abstract.
39. ®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2012;53(2):254-258.
40. Illidge TM, Bayne M, Brown NS, et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113:1412-1421.
41. Shah J, Wang W, Harrough VD, et al. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2007;48(9):1736-1744.
42. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23(31):7985-7993.
43. Illidge TM, Pettengell R, Bayne M, et al. Fractionated 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy as an initial therapy of follicular lymphoma: fi rst results from a phase II study in patients requiring treatment according to GELF/BNLI criteria. Blood (ASH Annual Meeting Abstracts). 2011;118(21):102.
44. Jankowitz R, Joyce J, Jacobs SA. Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma. Clin Nucl Med. 2008;33(2):94-96.
45. Morschhauser F, Kraeber-Bodéré F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(23):3709-3716.
46. Ma D, McDevitt MR, Barendswaard E, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia. 2002;16(1):60-66.
47. Vallera DA, Elson M, Brechbiel MW, et al. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm. 2004;19(1):11-23.
48. Gopal AK, Pagel JM, Fromm JR, et al. 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood. 2009;113(23):5905-5910.
49. Michel RB, Rosario AV, Brechbiel MW, et al. Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74. Nucl Med Biol. 2003;30(7):715-723.
50. Orcutt KD, Nasr KA, Whitehead DG, et al. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol. 2011;13(2):215-221.
51. Sharkey RM, Karacay H, Johnson CR, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med. 2009;50(3): 444-453.
52. Jóhannsson J, Specht L, Mejer J, et al. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys. 2002;54(5):1466-1470.
53. Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved fi eld radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474-480.
54. Luthy SK, Ng AK, Silver B, et al. Response to low-dose involvedfi eld radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol. 2008;19(12):2043-2047.
55. Burdick MJ, Neumann D, Pohlman B, et al. External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma. Int J Radiat Oncol Biol Phys. 2011;79(4):1124-1130.
56. Tomblyn M. Addition of low-dose, involved-fi eld external beam radiotherapy just prior to radioimmunotherapy for B-cell lymphoma: "priming" cell death pathways. J Clin Oncol. 2011;29(suppl):e18533. Abstract.
57. Gupta D, Crosby ME, Almasan A, et al. Regulation of CD20 expression by radiation-induced changes in intracellular redox status. Free Radic Biol Med. 2008;44(4):614-623.
58. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25(27):4285-4292.
59. Pedersen-Bjergaard J, Ersbøll J, Sørensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med. 1985;103(2):195-200.
60. Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28(33):4935-4944.